| View printer-friendly version |
| Back |
|
FTI Consulting Survey Shows Life Sciences Leaders’ Outlook Tempered by Concerns Around Fundraising, Policy Shifts and Cybersecurity Heading into 2026
|
Key Legislation Expected to Impact Supply Chain and Drug Costs
Recent M&A Momentum Offset by Challenging Fundraising Environment
Artificial Intelligence (AI) Seen as Key Investment Area
The survey indicates that while optimism persists in some areas, industry leaders are navigating significant challenges within the capital markets, evolving political and regulatory landscapes, and have ongoing cybersecurity concerns.
“As we look towards 2026, life sciences companies face a complex landscape of shifting financial and regulatory factors, which demand strategic agility,” said Robert Stanislaro, Head of the Healthcare & Life Sciences’ Corporate Reputation offering within FTI Consulting’s
Policy and Regulatory Challenges
A year into President Trump’s second presidency, life sciences leaders remain divided (51% positive versus 49% negative) about his impact on the industry to-date. Notably, respondents view Secretary of Health and Human Services
Despite economic headwinds, 59% of respondents plan to allocate additional budget to AI and large-language models in 2026. Organizations are expecting to implement AI across multiple functions, including for the development of internal content (41%), internal operations (38%), financial analysis (37%), patient support/hub services (34%), and personalized marketing (31%). In communications specifically, leaders see AI offering the greatest opportunities in social and digital communications (63%), media engagement (48%), issues management (48%), thought leadership (47%), and earnings/investor communications (45%).
Cybersecurity Concerns
The survey also reveals concerning trends in cybersecurity readiness. Nearly half (47%) of respondents perceive their organizations as vulnerable to cyber incidents. However, only 60% of respondents have a crisis communications plan in place, down from 68% in 2025, and participation in simulation exercises has dropped to 47% from 53% in 2025.
Transactions & Capital Markets Activity
While 65% of respondents expect M&A activity to be higher in 2026, only 54% of leaders are optimistic about increased IPO activity, representing a 7% drop from 2025. The fundraising environment is also predicted to be increasingly challenging, with only 28% of respondents believing that it will be easier to raise capital in 2026.
“Our findings reveal a life sciences industry that remains resilient but increasingly cautious as we enter 2026,” said
The full survey report is available here.
About the Survey
This research was conducted online by FTI Consulting’s
About
555 12th Street NW
+1.202.312.9100
Investor Contact:
+1.617.747.1791
mollie.hawkes@fticonsulting.com
Media Contact:
+1.617.510.1676
nick.emmons@fticonsulting.com
Source: FTI Consulting, Inc.